Drug Trial Radar · NCT04644185
The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19
Last checked: Nov 19, 2026Latest source record: Oct 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
102
Actual
Start
Mar 27, 2021
Primary completion
Dec 29, 2021
Study completion Feb 11, 2022
Sponsor
- Lead sponsor
- Sinocelltech Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 25, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a multicenter, adaptive, randomized, double-blinded and placebo-controlled Phase II/III trial, and will be conducted globally. The study is comprised of two parts: dose selection (Phase II) and pivotal treatment effect (Phase III).
Conditions
- Covid19
Interventions
SCTA01Drug
SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
PlaceboOther
all SCTA01 excipients without active component+best supportive care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Clinical Improvement up to Day 29Time frame: Day 29
Locations
7 sites in 7 countries. Site status is shown where the registry gives one.
SCT study site
Somers Point, New Jersey
SCT study site
Buenos Aires, Argentina
SCT study site
Uberlândia, Brazil
SCT study site
Talca, Chile
SCT study site
Rionegro, Colombia
SCT study site
Monterrey, Mexico
SCT study site
Lima, Peru
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.